Gram-Positive Bacterial Infections Market Dynamics and Developments by 2031

Coverage: By Disease (Methicillin-resistant Staphylococcus aureus (MRSA), Pneumonia, Sepsis, Sinusitis, Skin Disorders, Other Diseases); Drug Type (Antibiotic, Antifungal, Others); Route of Administration (Enteral, Parenteral, Others); Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Other Distribution Channels) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2023 | Base Year: 2024 | Forecast Period: 2025-2031
  • Status : Data Released
  • Report Code : TIPRE00004059
  • Category : Life Sciences
  • No. of Pages : 150
  • Available Report Formats : pdf-format excel-format
  • Last update date : January 27, 2025
Gram-Positive Bacterial Infections Market Dynamics and Developments by 2031
Report Date: January 27, 2025   |   Report Code: TIPRE00004059 Email: sales@theinsightpartners.com

2024 Market Size

US$ 14.70 Bn

Base year value

2031 Forecast

US$ 17.83 Bn

Projected by 2031

CAGR 2025-2031

2.8 %

Growth rate

Addressable Market

US$ 115.09 Bn

(2025-2031)

The Gram Positive Bacterial Infections Market size is expected to reach US$ 17.83 Billion by 2031. The market is anticipated to register a CAGR of 2.8% during 2025-2031.

The Gram-positive Bacterial Infections Market report covers analysis By Disease (Methicillin-resistant Staphylococcus aureus (MRSA), Pneumonia, Sepsis, Sinusitis, Skin Disorders, Other Diseases); Drug Type (Antibiotic, Antifungal, Others); Route of Administration (Enteral, Parenteral, Others); Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Other Distribution Channels). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.

Purpose of the Report

The report Gram-positive Bacterial Infections Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Gram-positive Bacterial Infections Market Segmentation Disease

  1. Methicillin-resistant Staphylococcus aureus
  2. Pneumonia
  3. Sepsis
  4. Sinusitis
  5. Skin Disorders
  6. Other Diseases

Drug Type

  1. Antibiotic
  2. Antifungal
  3. Others

Route of Administration

  1. Enteral
  2. Parenteral
  3. Others

Distribution Channel

  1. Hospital Pharmacies
  2. Drug Stores and Retail Pharmacies
  3. Other Distribution Channels

Market Research Highlights

  • Global market for Gram-positive Bacterial Infections was valued at US$ 14.70 Billion in 2024
  • Annual market size is expected to reach US$ 17.83 Billion by 2031
  • Total addressable market (TAM) during 2025-2031 is projected to reach approximately US$ 115.09 Billion
  • Market is anticipated to register a CAGR of 2.8% during the forecast period
  • The United States represents a key market, supported by Rising Antimicrobial Resistance, Advancements in Drug Development, Increased Healthcare Spending, as well as evolving industry dynamics
  • Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
  • Market opportunities such as Research and Development, Emerging Markets, Innovative Therapeutic Approaches are expected to influence market dynamics and addressable market
  • Report profiles industry participants, including Abbvie, AstraZeneca, Bayer AG, GlaxoSmithKline plc., Merck Sharp and Dohme Corp., NovaBiotics Ltd, Novartis AG, Pfizer Inc., Sanofi, Dr. Reddy's Laboratories Inc, Cipla, Alembic Pharmaceuticals, Mankind Pharma, Intas, while analyzing competitive strategies and innovation developments
  • Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

  • Segmentations
  • Geography
  • Competitive Analysis
  • Language Preferences

Gram-positive Bacterial Infections Market: Strategic Insights

gram-positive-bacterial-infections-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Gram-positive Bacterial Infections Market Growth Drivers

  1. Rising Antimicrobial Resistance: Market analysis suggests the imperative need for new antibiotics targeting gram-positive pathogens, which will increase the market size.
  2. Advancements in Drug Development: Competitive analysis shows the R&D efforts that have been generating strong, broad-spectrum therapies, and this has shaped the growth of the global market.
  3. Increased Healthcare Spending: According to market reports, higher investment in infection management and control supports market trends and expansion globally.

Gram-positive Bacterial Infections Market Future Trends

  1. Increasing Antibiotic Resistance: The emergence of resistant strains like MRSA is pushing for innovative antibiotics and alternative therapies.
  2. Advancements in Diagnostics: New and improved diagnostic technologies enable faster and more accurate detection of Gram-positive bacterial infections, improving treatment outcomes.
  3. Adoption of Combination Therapies: The use of combination treatments is gaining popularity to enhance efficacy against resistant bacterial strains.

Gram-positive Bacterial Infections Market Opportunities

  1. Research and Development: Continued investment in R&D offers the potential for breakthrough therapies to address antibiotic resistance challenges.
  2. Emerging Markets: Regions with improving healthcare infrastructure and growing awareness about infectious diseases present significant growth opportunities.
  3. Innovative Therapeutic Approaches: The development of biologics and phage therapies as alternatives to traditional antibiotics is creating new avenues in the market.

Gram-positive Bacterial Infections Market Report Scope

Report Attribute Details
Market size in 2024 US$ 14.70 Billion
Market Size by 2031 US$ 17.83 Billion
Global CAGR (2025 - 2031) 2.8%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Disease
  • Methicillin-resistant Staphylococcus aureus
  • Pneumonia
  • Sepsis
  • Sinusitis
  • Skin Disorders
  • Other Diseases
By Drug Type
  • Antibiotic
  • Antifungal
  • Others
By Route of Administration
  • Enteral
  • Parenteral
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Other Distribution Channels
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbvie
  • AstraZeneca
  • Bayer AG
  • GlaxoSmithKline plc.
  • Merck Sharp and Dohme Corp.
  • NovaBiotics Ltd
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Dr. Reddy's Laboratories Inc
  • Cipla
  • Alembic Pharmaceuticals
  • Mankind Pharma
  • Intas

Gram-positive Bacterial Infections Market Players Density: Understanding Its Impact on Business Dynamics

The Gram-positive Bacterial Infections Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

gram-positive-bacterial-infections-market-cagr

Key Selling Points

  1. Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Gram-positive Bacterial Infections Market, providing a holistic landscape.
  2. Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  3. Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  4. Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Gram-positive Bacterial Infections Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


Frequently Asked Questions

The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.

Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.

Key companies of this market are: Abbvie, AstraZeneca, Bayer AG, GlaxoSmithKline plc., Merck Sharp and Dohme Corp., NovaBiotics Ltd, Novartis AG, Pfizer Inc., Sanofi

Key future trends in this market are - Rising Antibiotic Resistance, Focus on Narrow-Spectrum Antibiotics, Expanding Role of Combination Therapies

The Gram-positive Bacterial Infections Market is estimated to witness a CAGR of 2.8% from 2025 to 2031.

The major factors driving the market are: Growing antimicrobial resistance concern, Advances in antibiotic development, Increased healthcare spending globally.
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA